How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Activin and Inhibin Market
- By Product Type: Activin A, Activin B, Activin AB, Inhibin A, Inhibin B
- By Application: Fertility and Reproductive Health, Cancer Diagnosis and Therapy, Inflammatory Disease Research, Endocrine Disorder Studies, Regenerative Medicine
- By End User: Pharmaceutical and Biotechnology Companies, Research Laboratories, Diagnostic Laboratories, Academic and Research Institutions, Contract Research Organizations (CROs)
- By Form: Recombinant Proteins, Antibodies, ELISA Kits, Assay Kits, Synthetic Peptides
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Activin A leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Activin and Inhibin Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Form 5
Companies profiled
R&D Systems (Bio-Techne Corporation)
Abcam plc
Thermo Fisher Scientific Inc.
Sigma-Aldrich (Merck KGaA)
BioVision Inc.
MyBioSource Inc.
Cusabio Biotech Co. Ltd.
Cloud-Clone Corp.
RayBiotech Inc.
Elabscience Biotechnology Inc.
Wuhan Fine Biotech Co. Ltd.
Sino Biological Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →R&D Systems (Bio-Techne Corporation)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abcam plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sigma-Aldrich (Merck KGaA)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BioVision Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →MyBioSource Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cusabio Biotech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Cloud-Clone Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →RayBiotech Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Elabscience Biotechnology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Wuhan Fine Biotech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sino Biological Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Aviva Systems Biology
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →GenScript Biotech Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Abbexa Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,529M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Activin A29.7
- Activin B10.4
- Activin AB23.1
- Inhibin A19.1
- Inhibin B17.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,840M → $4,168M · 10.8%
Europe$1,283M → $3,159M · 11.9%
Asia Pacific$1,171M → $2,397M · 9.4%
Latin America$724.9M → $1,757M · 11.7%
Middle East and Africa$557.6M → $1,393M · 12.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.592026
10.602027
10.622028
10.632029
10.662030
10.662031
10.672032
10.682033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- R&D Systems (Bio-Techne Corporation)20.6
- Abcam plc23.1
- Thermo Fisher Scientific Inc.4.2
- Sigma-Aldrich (Merck KGaA)3.3
- BioVision Inc.10.2
- MyBioSource Inc.10.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type31.9%
Application20.4%
End User21.0%
Form26.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.4
- Europe24.5
- Asia Pacific18.6
- Latin America13.6
- Middle East and Africa10.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| R&D Systems (Bio-Techne Corporation) | 96 | 95 | 85 | 84 | 90 | 91 | 90 |
| Abcam plc | 91 | 90 | 77 | 92 | 90 | 69 | 85 |
| Thermo Fisher Scientific Inc. | 80 | 87 | 86 | 70 | 79 | 83 | 81 |
| Sigma-Aldrich (Merck KGaA) | 72 | 60 | 65 | 81 | 77 | 61 | 69 |
| BioVision Inc. | 53 | 65 | 63 | 66 | 61 | 54 | 60 |
| MyBioSource Inc. | 52 | 46 | 68 | 62 | 63 | 62 | 59 |
| Cusabio Biotech Co. Ltd. | 49 | 48 | 49 | 59 | 50 | 51 | 51 |
| Cloud-Clone Corp. | 56 | 60 | 57 | 55 | 54 | 56 | 56 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- R&D Systems (Bio-Techne Corporation)
- Abcam plc
- Thermo Fisher Scientific Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| R&D Systems (Bio-Techne Corporation) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Abcam plc | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Sigma-Aldrich (Merck KGaA) | ◐ | − | − | ✓ | ◐ | ◐ |
| BioVision Inc. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| MyBioSource Inc. | − | − | − | − | − | ◐ |
| Cusabio Biotech Co. Ltd. | ◐ | ◐ | ◐ | ◐ | − | − |
| Cloud-Clone Corp. | ◐ | ◐ | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1R&D Systems (Bio-Techne Corporation)90
2Abcam plc85
3Thermo Fisher Scientific Inc.81
4Sigma-Aldrich (Merck KGaA)69
5BioVision Inc.60
6MyBioSource Inc.59
7Cloud-Clone Corp.56
8Cusabio Biotech Co. Ltd.51
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
R&D Systems (Bio-Techne Corporation)Abcam plcThermo Fisher Scientific Inc.
Challenger1
Strong scale, closing on the leaders.
Sigma-Aldrich (Merck KGaA)
Contender2
Focused players with pockets of strength.
BioVision Inc.MyBioSource Inc.
Niche2
Specialists in a single segment or region.
Cusabio Biotech Co. Ltd.Cloud-Clone Corp.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Activin and Inhibin Market — a $523M beachhead inside a $9.00B market.
Beachhead (SOM)$523Mobtainable near-term
Serviceable (SAM)$3.12Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Activin A
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
Activin B
Strong fit — clear ROI and a fast path to value.
End user70 fit
Activin AB
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Activin and Inhibin Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation14%
Closed-won6%
$20.0KCAC
$105KLTV
5.3:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Activin and Inhibin Market is a durable-growth opportunity — $6.25B by 2033, compounding at 8.0%.
TAM · 2025$3.37Btoday
TAM · 2033$6.25Bforecast
CAGR8.0%2027–2033
Cumulative$42.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.25BTotal addressable market
SAM$2.54BServiceable available market
SOM$526MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.25BLarge & growingTAM by 2033 at 8.0% CAGR
$2.54BServiceable nowreachable with today’s model
$526MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.87BBear5.2% CAGR
$6.25BBase8.0% CAGR
$7.99BBull10.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Activin and Inhibin Market — a $4.15B market by 2033. Plan: grow share from 8.4% to 16.6%.
Market size · 2033$4.15Btotal addressable
Market CAGR4.0%2027–2033
Target share16.6%from 8.4% today
Revenue ambition$689Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 16.6% | On track |
| Revenue | $363M | $689M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.0% | 44.3% | At risk |
| Customer retention | 85.6% | 92.8% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $87M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Activin and Inhibin Market conversation — a $4.09B market you can size, segment and defend in minutes.
Market size · 2033$4.09Btotal opportunity
Growth9.1%CAGR to 2033
Addressable buyers1,414+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 2 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
R&D Systems (Bio-Techne Corporation)Abcam plcThermo Fisher Scientific Inc.Sigma-Aldrich (Merck KGaA)BioVision Inc.MyBioSource Inc.Cusabio Biotech Co. Ltd.Cloud-Clone Corp.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Activin and Inhibin Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Activin and Inhibin Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Airway Needle Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportMenotropin Market
Market size, share, segmentation and regional forecast.
$857M market · 2025 base year
View reportAirway Mucus Clearance Device Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAirway Monitoring Systems Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportAirway Management Resuscitation Devices Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportPlant-based Cannabidiol (CBD) Nutraceuticals Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAirway Management Devices Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportAsenapine Market
Market size, share, segmentation and regional forecast.
$977M market · 2025 base year
View reportAirway Hollow Stent Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportDNA Purification Kits Market
Market size, share, segmentation and regional forecast.
$949M market · 2025 base year
View reportAirway Endoscopes Market
Market size, share, segmentation and regional forecast.
$923M market · 2025 base year
View reportHuman Recombinant Insulin Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.